ROME, November 25-26, 2014
AUDITORIUM, MINISTRY OF HEALTH

EACS | European AIDS Clinical Society MEETING

“STANDARD of CARE for HIV and COINFECTIONS in EUROPE”

Chairs: A. Antinori, A. d’Arminio Monforte, C. Mussini
2014 European Guideline on HIV Testing

Deniz Gökengin
Ege University Faculty of Medicine
Department of Infectious Diseases and Clinical Microbiology
Izmir TURKEY
Presentation Plan

• Purpose and aim of the guideline
• What is new in the guideline and what is the rationale behind the change?
• What do we expect?
Guidelines

2014 European Guideline on HIV testing

Deniz Gökengin¹, Anna Maria Geretti², Josip Begovac³, Adrian Palfreeman⁴, Milena Stevanovic⁵, Olga Tarasenko⁶ and Keith Radcliffe⁷

Abstract
Testing for HIV is one of the cornerstones in the fight against HIV spread. The 2014 European Guideline on HIV Testing provides advice on testing for HIV infection in individuals aged 16 years and older who present to sexually transmitted infection, genito-urinary or dermato-venereology clinics across Europe. It may also be applied in other clinical settings where HIV testing is required, particularly in primary care settings. The aim of the guideline is to provide practical guidance to clinicians and laboratories that within these settings undertake HIV testing, and to indicate standards for best practice.
They're the draft guidelines on how to run a 'paperless' office.
Purpose of the guideline

- To provide advice on testing for HIV infection in individuals aged 16 years or older who present to STI, genito-urinary (GU) or dermato-venereology (DV) clinics across Europe.
Aim of the guideline

• To provide practical guidance to clinicians and laboratories that in these settings undertake HIV testing and to indicate standards for best practice.
What is new in the guideline?

• Changes in format
  – Number of subheadings increased for a more reader-friendly format
  – Recommendations for the clinician and the laboratory separated
  – Minor changes in wording and sentence format
Changes in content
• The setting redefined
  – to include STI, GU and DV clinics
  – primary care also mentioned
Benefits and harms of HIV testing

• Emphasis on adverse effects of HIV diagnosis on sexual and risk taking behavior
• Negative implications
Benefits of HIV testing

• Early diagnosis and early onset of ART
  – Life expectancy and QoL improved$^{1-5}$(Ib)
  – Risk of HIV transmission decreased$^{6}$(Ia)
  – Sexual and needle sharing behaviors significantly reduced$^{7-13}$(Ia)

7 Desenclos J-C, et al. AIDS 1993
9 Gibson DR, et al. AIDS Behav 1999
11 Crepaz N, et al. AIDS 2006
When to consider testing

- All individuals who seek care in STI/GU/DV clinics
- Individuals whose history suggests a high likelihood of being exposed to HIV
- Pregnant women
- Persons who voluntarily seek testing, especially if they have never been tested before
When to consider testing

• Testing frequency
  – Every 12 months seems reasonable unless specific aspects of risk behaviour warrant more frequent testing (eg. Every 3-4 mo) (IVC)
  – Testing frequency should be based in part on the level of risk and requires a dialogue between the provider and the patient, which will require test history and any risk behaviours. (IVC)
Pre-test Assessment

• Shortened and simplified
• Introduction paragraph
  – Importance of informed consent
  – Assessment of the window period
• Components of pretesting assessment
  – Obtain HIV testing history
  – Offer testing for other STIs
  – Offer PEPSE if indicated and available
Other Subheadings

- Individuals who may require more in-depth pretest discussion
  - Removed
- Informed consent* (IIIB)
- Testing without informed consent
- Confidentiality
  - the use of a number or a false name may be an option «where available» for individuals who decline HIV testing due to concerns about confidentiality

*Zetola NM. JAMA 2007
Samples

• Samples other than venous blood should be subjected to rigorous training and quality assurance
2008 Guideline
• Testing for HIV
  – Type of test
  – Confirmation of positive results
  – Quality control

2014 Guideline
• Recommendations for the laboratory
  – HIV screening and confirmatory tests
    • Screening serology test
    • Confirmation of reactive serology results
    • Confirmation of indeterminate/equivocal screening results
    • Recent HIV infection
    • Quality control
Screening serology test

• Strong emphasis on the use of fourth generation assays that simultaneously test for anti-HIV antibodies and p24 antigen as screening tests
Confirmation of reactive serology

- Confirmatory algorithms may vary. Generally they include at least one additional antibody or antibody/antigen serology test that employs a different platform from the initial screening test.\(^1\) (IIIB)

- It may be replaced by testing a plasma sample for HIV-1 RNA, provided the viral load is >1000 c/mL. In patients with a lower or undetectable VL a second serum sample should be collected for repeat serological testing. (IVC)

1UNAIDS-WHO Wkly Epidemiol Rec 1997
Confirmation of indeterminate results

- False reactivity/early HIV infection
- All patients with an initial indeterminate result should undergo repeat testing 1-2 weeks later (IVC)
- When there is strong suspicion of recent infection HIV-1 RNA or (in some cases p24 antigen) may be tested (IVC)
Recent HIV infection

• NAATs are not recommended for screening\(^{(1-3)}\)

• Suspected primary infection but negative serology\(\rightarrow\)HIV RNA testing
  – HIV RNA (+)\(\rightarrow\) Show seroconversion 1-2 wks later
  – Low RNA values\(\rightarrow\) interpret with caution (IIb)

• NAATs not available/affordable\(\rightarrow\)repeat serology 1-2 wks later (IVC)

1Rich JD. Ann Intern Med 1999
2Serman GG. Pediatr Infect Dis 2005
3Marinovich A. J Clin Microbiol 2006
Quality control

• Where a national accreditation scheme is not available, testing should be undertaken only under approved (e.g., CE) tests under a strict quality assurance program; quality assurance results should be made available for inspection where required.
Interpreting negative test results

- Earlier detection of HIV with 4th gen assays\textsuperscript{1-3}
- Variability in analytical sensitivity of assays\textsuperscript{6-8}
- Second diagnostic window\textsuperscript{4-5}
- Recent HIV infection may be missed\textsuperscript{9}

1. Sickinger E. J Clin Microbiol 2004
3. Taylor D. Int J STD AIDS 2014
4. Speers D. J Clin Microbiol 2005
8. Ly TD. Virol 2012
Interpreting negative test results

• Person received PEP
• Patient very anxious and requires further reassurance
• Impaired ability to develop antibodies
• Microbiologically proven simultaneous acute infection with another viral pathogen (CMV, HCV)
Point-of-care Tests

- Reduced sensitivity\(^1\)\(^{-6}\)
  - False negative results
- PPV reduced in low prevalence settings\(^7\)
- More variation in assay performance and sensitivity for POC tests that use other samples\(^2,8\)
- Obtain a blood sample (II,B)
- Self-testing for HIV\(^9\)\(^{-11}\)
- Quality assurance program

2. Wesolowski LG. AIDS 2006
12. WHO Guideline 2004
13. CDC Guideline 2007
Post-test issues

• Post-test discussion for individuals who are negative
  – PEP recommendation moved to pre-test assessment section

• Post-test discussion for individuals who are positive
  – «accepting the possibility of a short life span» replaced by «accepting to live with a chronic condition»
What do we expect?

• Guidelines are not strict rules, they include recommendations
  – Evidence based
  – Expert opinions

• Uptake of recommendations by HCP or healthcare seekers variable
• Awareness of non-HIV HCPs on UK guidelines (2008)
  – 67% unaware of new guidelines
  – 26% aware but did not read
  – 3% aware and read
• Mean barrier for HIV testing is
  – lack of training (63%)
  – concerns about pre-test discussion (60%)
  – concerns about consent (40%)
HIV testing: getting the message across—a survey of knowledge, attitudes and practice among non-HIV specialist physicians

Ewan Hunter.\textsuperscript{1} Meghan Perrv.\textsuperscript{2} Clifford Leen.\textsuperscript{2} Nikhil Premchand\textsuperscript{1}

- Awareness of non-HIV physicians regarding HIV testing in patients with indicator diseases
  - 88% unaware of BHIVA guidelines
- Most common perceived barriers
  - low-risk population (48%)
  - lack of patient acceptance (35%)
  - consent process/pretest counselling (33%)

Postgrd Med J 2012
• Promotion
• Training
• Follow-up
Acknowledgements

• IUSTI Guidelines Chief Editor and co-author
  – Keith Radcliffe
• Co-authors
  – Josip Begovac
  – Anna Maria Geretti
  – Adrian Palfreeman
  – Milena Stevanovic
  – Olga Tarasenko